Other Events ·
aTyr Pharma announced a corporate restructuring involving an approximately 60% workforce reduction to conserve capital…
ATYRaTYR PHARMA Inc
aTyr Pharma announced a corporate restructuring involving an approximately 60% workforce reduction to conserve capital and prioritize its lead asset, efzofitimod, for interstitial lung disease. The company expects these measures to reduce annualized operating expenses by $13 million starting in Q4 2026. Key executive changes include CFO Jill Broadfoot stepping down on September 30, 2026, with VP Brandon Yaras succeeding her on October 1, 2026; General Counsel Nancy Denyes also steps down as a consultant. Financially, the company held $58.9 million in cash and investments at June 30, 2026, providing a runway into late 2028. The firm submitted a Phase 3 protocol for efzofitimod in pulmonary sarcoidosis to the FDA in June 2026 and awaits feedback by August 2026. Enrollment is complete in the Phase 2 EFZO-CONNECT study for SSc-ILD, with top-line results expected in Q1 2027. aTyr Pharma operates as a clinical-stage biotechnology company focused on discovering therapies from its proprietary tRNA synthetase platform.